As of 2025-12-24, the EV/EBITDA ratio of Acceleron Pharma Inc (XLRN) is -41.25. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Acceleron's latest enterprise value is 10,456.47 mil USD. Acceleron's TTM EBITDA according to its financial statements is -253.46 mil USD. Dividing these 2 quantities gives us the above Acceleron EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.3x - 15.5x | 15.2x |
| Forward P/E multiples | 17.3x - 35.5x | 22.1x |
| Fair Price | (67.05) - (59.58) | (72.72) |
| Upside | -137.5% - -133.3% | -140.7% |
| Date | EV/EBITDA |